Hemophilia Genetic Diagnosis Using Targeted PCR and Sequencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genetic testing methods for diagnosing hemophilia A, hemophilia B, and von Willebrand disease (VWD) are time-consuming, often taking at least a week, which hinders rapid patient diagnosis and management.
Innovation Solution
A method involving the amplification of genetic material using specific primers for the F8, F9, and VWF genes, followed by DNA sequencing and comparison with a normal control, allowing for the rapid identification of mutations, polymorphisms, and structural variants associated with these bleeding disorders within 48 hours or 5 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If traditional genetic testing methods are used to diagnose hemophilia and VWD, then diagnostic accuracy is maintained, but the testing time is extended to at least a week
Solution Approach 1:
The patent divides the genetic testing process into distinct segments: DNA extraction, PCR amplification of specific genes (F8, F9, VWF), and sequence analysis. By segmenting the workflow and optimizing each step, the overall testing time is reduced from over a week to approximately 48 hours while maintaining diagnostic accuracy for hemophilia and VWD
Solution Approach 2:
The patent performs preliminary actions by pre-designing and preparing specific primers for the F8, F9, and VWF genes before patient sample processing. This preliminary preparation of targeted amplification regions enables rapid PCR amplification and sequencing, significantly reducing the time required from sample receipt to diagnostic result without compromising test sensitivity or specificity
2Productivity
If rapid genetic testing is implemented to reduce diagnosis time to 48 hours, then patient management speed is improved, but testing accuracy and reliability may be compromised
Solution Approach 1:
The patent applies local quality by focusing the rapid testing protocol on specific high-priority gene regions (F8 for hemophilia A, F9 for hemophilia B, and VWF for von Willebrand disease) rather than performing whole-genome sequencing. This targeted approach maintains diagnostic accuracy for these specific conditions while reducing overall testing time and complexity
Solution Approach 2:
The patent incorporates feedback mechanisms through quality control measures at multiple stages: primer design validation, PCR amplification efficiency monitoring, and sequence analysis verification. These feedback loops ensure that the accelerated 48-hour testing protocol maintains the same diagnostic reliability as traditional extended protocols by continuously monitoring and adjusting critical parameters
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid diagnosis and risk assessment for hemophilia A, hemophilia B, and VWD, facilitating timely treatment and management by identifying genetic alterations in a significantly shorter timeframe than traditional methods.
Implementation Method 1
amplifying the genetic material using two or more primers specific for the genes underlying hemophilia A, hemophilia B or VWD
Implementation Method 2
determining the DNA sequence of the amplified genetic material
Data Source
AI summary
A method for determining a subject's risk for developing hemophilia A, hemophilia B, or von Willebrand disease (VWD) is described. The method involves obtaining a sample of genetic material from the subject. The genetic material is amplifed using primers specific for the genes underlying hemophilia A, hemophilia B and VWD. The DNA sequence of the amplified genetic material is determined and compared with a DNA sequence from a normal control subject. One or more DNA sequence alterations in the amplified genetic material not present in the DNA sequence from the normal control subject indicates that the subject is at risk for developing hemophilia A, hemophilia B, or VWD.